Glaucoma Treatment Market

Glaucoma Treatment Market [Product Type: Prostaglandin Analogs (PGAs), Alpha Agonist, Beta Blockers, Cholinergic, Carbonic Anhydrase Inhibitors, Combined Medications] - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Market Outlook 2031

  • The global glaucoma treatment market size stood at US$ 6.3 Bn in 2022
  • It is expected to increase at a CAGR of 4.3% from 2023 to 2031 and reach US$ 9.1 Bn by the end of 2031

Analyst Viewpoint

Vision impairment or blindness is a serious health issue across the globe. The third-most common cause of blindness is glaucoma. If detected early, the progression of glaucoma can be stabilized or prevented through medical and surgical therapy. Rise in awareness and screening campaigns about glaucoma and the efficacy of fixed-dose combination products, which can help prevent the need for complex eye surgeries in the near future, is likely to boost the glaucoma treatment market growth in the next few years.

Leading pharmaceutical players are investing significantly in the development of innovative technologies for early glaucoma detection and treatment owing to the large incidence of this disease. Furthermore, rise in approvals for intraocular pressure (IOP) lowering drugs is expected to create lucrative glaucoma treatment market opportunities for several manufacturers in the next few years.

Glaucoma Treatment Market

Market Introduction

Glaucoma is the degeneration of retinal ganglion cells and retinal nerve fiber layers, which may result in alteration in optical nerve head. Glaucoma is among the leading causes of irreversible blindness across the globe. Causes could include excessive smoking, vasospasm, age and frailty, myopia, systemic hypertension and hypotension, migraine, obstructive sleep apnea syndrome, increased IOP, and usage of steroids.

Latest innovation in glaucoma eye treatment, such as selective laser trabeculoplasty (SLT), medical imaging, optical coherence tomography (OCT), microinvasive glaucoma surgery (MIGS), visual fields, and progression analysis software are helping in the early diagnosis. This is expected to help in cure of glaucoma through over-the-counter fixed-combination dosages.

The post-COVID era changed the dynamics of screen time. Hybrid work models increased the time in front of screens, laptops, and smartphones. This is a key factor that fueled the incidences of glaucoma and consequently, augmented the demand for intraocular pressure management.

Development of Fixed-Dose Combination Products Propelling Glaucoma Treatment Market Growth

Currently, more than half of the patients suffering from glaucoma consume more than one drug at a time; however, a majority of patients do not adhere to the norms put forward by healthcare personnel regarding dosage of medications. Additionally, as there are no immediate negative consequences of this non-adherence, the patients do not get motivated to be concerned about compliance.

Increase in awareness regarding importance of bringing glaucoma under check has led to the development of fixed-dose combination products. Increase in demand for these products is expected to positively impact the global market scenario in the next few years.

Rise in Incidence of Glaucoma Augmenting Glaucoma Treatment Market Value

As per the WHO, 2.2 billion people worldwide have a distance or near vision impairment. It further states that at around 1 billion out of these are suffering from vision impairment that could have been averted or at least addressed earlier. Furthermore, according to WHO, in 2020, glaucoma affected 76 million people worldwide.

The geriatric population is more prone to glaucoma; however, increase in screen time of smartphones and laptops amongst those aged 10 and above is also leading to glaucoma. As per the International Agency of the Prevention of Blindness, more than 2% of the U.S. population aged 40 and above has glaucoma. Therefore, increase in prevalence of glaucoma across the globe is anticipated to influence the future analysis of glaucoma treatment market during the forecast period.

Regional Glaucoma Treatment Market Insights

North America accounted for the largest glaucoma treatment market share in 2022 due to the presence of well-established hospital infrastructure to diagnose and treat glaucoma. Timely diagnosis facilitates efficient treatment, as glaucoma is slowly progressing ailment.

Existence of favorable reimbursement scenario, subsidies offered by The National Health Services (NHS) for the treatment of glaucoma, rise in research on glaucoma treatment, and innovations in technology across the European Union are projected to drive Europe’s glaucoma treatment market size in the upcoming years.

Increase in number of geriatric population, growth in spending on healthcare in developing countries across Asia Pacific and surge in number of diabetic patients with a family history of glaucoma are key factors that are expected to drive the glaucoma treatment market development in Asia Pacific at a rapid pace during the forecast period.

Analysis of Key Players

The glaucoma treatment industry is highly consolidated owing to the presence of prominent players with significant global presence. Leading producers of glaucoma treatment drugs are focusing on the production of generic drugs, which is hampering the launch of new therapies, as exclusivity of banded drugs would be lost. A few prominent entities operating in the global market are Novartis AG, Pfizer, Inc., Merck & Co., Inc., Bausch & Lomb Inc., Allergan Plc, Perrigo Plc, Teva Pharmaceutical Industries Ltd., Akorn, Inc., and Mobius Therapeutics, LLC.

Key Developments

  • In December 2021, Aerie Pharmaceuticals, Inc. entered into collaboration with Santen Pharmaceuticals for developing and commercializing Rhopressa/Rhokiinsa and Roclanda/Rocklatan for treating glaucoma in India, China, Europe, Oceania, and parts of Latin America.
  • In March 2021, Teva Pharmaceuticals introduced the very first generic version AZOPT (brinzolamide ophthalmic suspension) 1% for treating open angle glaucoma as well as ocular hypertension all across the U.S.
  • In May 2020, AbbVie Inc. announced that it had completed strategic acquisition of Allergan plc with the objective of establishing itself as a leading player in glaucoma market.

Key players in the glaucoma treatment market report have been profiled based on various parameters such as company overview, business strategies, financial overview, product portfolio, and business segments.

Glaucoma Treatment Market Snapshot

Attribute Detail
Size in 2022 US$ 6.3 Bn
Forecast (Value) in 2031 US$ 9.1 Bn
Growth Rate (CAGR) 4.3%
Forecast Period 2023-2031
Historical Data Available for 2017-2021
Quantitative Units US$ Bn for Value
Market Analysis It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis.
Competition Landscape
  • Market share analysis by company (2022)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials
Format Electronic (PDF) + Excel
Market Segmentation
  • Product Type
    • Prostaglandin Analogs (PGAs)
    • Alpha Agonist
    • Beta Blockers
    • Cholinergic
    • Carbonic Anhydrase Inhibitors
    • Combined Medications
  • Indication
    • Angle Closure Glaucoma (ACG)
    • Open Angle Glaucoma (OAG)
    • Secondary Glaucoma
    • Congenital Glaucoma
    • Other Indications
  • Sales Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Sales
Regions Covered
  • North America
  • Europe
  • Asia Pacific
  • Rest of the World
Countries Covered
  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Rest of Asia Pacific
Companies Profiled
  • Novartis AG
  • Pfizer, Inc.
  • Merck & Co., Inc.
  • Bausch & Lomb Inc.
  • Allergan Plc
  • Perrigo Plc
  • Teva Pharmaceutical Industries Ltd.
  • Akorn, Inc.
  • Mobius Therapeutics, LLC
Customization Scope Available upon request
Pricing Available upon request

Frequently Asked Questions

How big was the glaucoma treatment market in 2022?

The global market was valued at US$ 6.3 Bn in 2022

How is glaucoma treatment industry expected to grow during the forecast period?

It is projected to grow at a CAGR of 4.3% from 2023 to 2031

What are the key factors driving the demand for glaucoma treatment?

Advent of fixed-dose combination products and rise in prevalence of glaucoma

Which glaucoma treatment segment held the largest share in 2022?

In terms of sales channel, the hospital pharmacies segment held largest share in 2022

Which region is expected to dominate the glaucoma treatment sector?

North America is estimated to dominate in the next few years

Who are the key glaucoma treatment product manufacturers?

Novartis AG, Pfizer, Inc., Merck & Co., Inc., Bausch & Lomb Inc., Allergan Plc, Perrigo Plc, Teva Pharmaceutical Industries Ltd., Akorn, Inc., and Mobius Therapeutics, LLC

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Glaucoma Treatment Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Product Definition

            4.1.2. Industry Evolution/Developments

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Glaucoma Treatment Market Analysis and Forecast, 2023–2031

    5. Key Insights

        5.1. Pipeline Analysis

        5.2. Key Product/Brand Analysis

        5.3. Key Mergers & Acquisitions

        5.4. COVID-19 Pandemic Impact on Industry

    6. Global Glaucoma Treatment Market Analysis and Forecast, by Product Type

        6.1. Introduction & Definition

        6.2. Key Findings/Developments

        6.3. Market Value Forecast, by Product Type, 2023–2031

            6.3.1. Prostaglandin Analogs (PGAs)

            6.3.2. Alpha Agonist

            6.3.3. Beta Blockers

            6.3.4. Cholinergic

            6.3.5. Carbonic Anhydrase Inhibitors

            6.3.6. Combined Medications

        6.4. Market Attractiveness Analysis, by Product Type

    7. Global Glaucoma Treatment Market Analysis and Forecast, by Indication

        7.1. Introduction & Definition

        7.2. Key Findings/Developments

        7.3. Market Value Forecast, by Indication, 2023–2031

            7.3.1. Angle Closure Glaucoma (ACG)

            7.3.2. Open Angle Glaucoma (OAG)

            7.3.3. Secondary Glaucoma

            7.3.4. Congenital Glaucoma

            7.3.5. Other Indications

        7.4. Market Attractiveness Analysis, by Indication

    8. Global Glaucoma Treatment Market Analysis and Forecast, by Sales Channel

        8.1. Introduction & Definition

        8.2. Key Findings/Developments

        8.3. Market Value Forecast, by Sales Channel, 2023–2031

            8.3.1. Hospital Pharmacies

            8.3.2. Retail Pharmacies

            8.3.3. Online Sales

        8.4. Market Attractiveness Analysis, by Sales Channel

    9. Global Glaucoma Treatment Market Analysis and Forecast, by Region

        9.1. Key Findings

        9.2. Market Value Forecast, by Region, 2023–2031

            9.2.1. North America

            9.2.2. Europe

            9.2.3. Asia Pacific

            9.2.4. Latin America

            9.2.5. Middle East & Africa

        9.3. Market Attractiveness Analysis, by Region

    10. North America Glaucoma Treatment Market Analysis and Forecast

        10.1. Introduction

        10.2. Key Findings

        10.3. Market Value Forecast, by Product Type, 2023–2031

            10.3.1. Prostaglandin Analogs (PGAs)

            10.3.2. Alpha Agonist

            10.3.3. Beta Blockers

            10.3.4. Cholinergic

            10.3.5. Carbonic Anhydrase Inhibitors

            10.3.6. Combined Medications

        10.4. Market Value Forecast, by Indication, 2023–2031

            10.4.1. Angle Closure Glaucoma (ACG)

            10.4.2. Open Angle Glaucoma (OAG)

            10.4.3. Secondary Glaucoma

            10.4.4. Congenital Glaucoma

            10.4.5. Other Indications

        10.5. Market Value Forecast, by Sales Channel, 2023–2031

            10.5.1. Hospital Pharmacies

            10.5.2. Retail Pharmacies

            10.5.3. Online Sales

        10.6. Market Value Forecast, by Country, 2023–2031

            10.6.1. U.S.

            10.6.2. Canada

        10.7. Market Attractiveness Analysis

            10.7.1. By Product Type

            10.7.2. By Indication

            10.7.3. By Sales Channel

            10.7.4. By Country

    11. Europe Glaucoma Treatment Market Analysis and Forecast

        11.1. Introduction

        11.2. Key Findings

        11.3. Market Value Forecast, by Product Type, 2023–2031

            11.3.1. Prostaglandin Analogs (PGAs)

            11.3.2. Alpha Agonist

            11.3.3. Beta Blockers

            11.3.4. Cholinergic

            11.3.5. Carbonic Anhydrase Inhibitors

            11.3.6. Combined Medications

        11.4. Market Value Forecast, by Indication, 2023–2031

            11.4.1. Angle Closure Glaucoma (ACG)

            11.4.2. Open Angle Glaucoma (OAG)

            11.4.3. Secondary Glaucoma

            11.4.4. Congenital Glaucoma

            11.4.5. Other Indications

        11.5. Market Value Forecast, by Sales Channel, 2023–2031

            11.5.1. Hospital Pharmacies

            11.5.2. Retail Pharmacies

            11.5.3. Online Sales

        11.6. Market Value Forecast, by Country/Sub-region, 2023–2031

            11.6.1. Germany

            11.6.2. U.K.

            11.6.3. France

            11.6.4. Italy

            11.6.5. Spain

            11.6.6. Rest of Europe

        11.7. Market Attractiveness Analysis

            11.7.1. By Product Type

            11.7.2. By Indication

            11.7.3. By Sales Channel

            11.7.4. By Country/Sub-region

    12. Asia Pacific Glaucoma Treatment Market Analysis and Forecast

        12.1. Introduction

        12.2. Key Findings

        12.3. Market Value Forecast, by Product Type, 2023–2031

            12.3.1. Prostaglandin Analogs (PGAs)

            12.3.2. Alpha Agonist

            12.3.3. Beta Blockers

            12.3.4. Cholinergic

            12.3.5. Carbonic Anhydrase Inhibitors

            12.3.6. Combined Medications

        12.4. Market Value Forecast, by Indication, 2023–2031

            12.4.1. Angle Closure Glaucoma (ACG)

            12.4.2. Open Angle Glaucoma (OAG)

            12.4.3. Secondary Glaucoma

            12.4.4. Congenital Glaucoma

            12.4.5. Other Indications

        12.5. Market Value Forecast, by Sales Channel, 2023–2031

            12.5.1. Hospital Pharmacies

            12.5.2. Retail Pharmacies

            12.5.3. Online Sales

        12.6. Market Value Forecast, by Country/Sub-region, 2023–2031

            12.6.1. China

            12.6.2. Japan

            12.6.3. India

            12.6.4. Australia & New Zealand

            12.6.5. Rest of Asia Pacific

        12.7. Market Attractiveness Analysis

            12.7.1. By Product Type

            12.7.2. By Indication

            12.7.3. By Sales Channel

            12.7.4. By Country/Sub-region

    13. Latin America Glaucoma Treatment Market Analysis and Forecast

        13.1. Introduction

        13.2. Key Findings

        13.3. Market Value Forecast, by Product Type, 2023–2031

            13.3.1. Prostaglandin Analogs (PGAs)

            13.3.2. Alpha Agonist

            13.3.3. Beta Blockers

            13.3.4. Cholinergic

            13.3.5. Carbonic Anhydrase Inhibitors

            13.3.6. Combined Medications

        13.4. Market Value Forecast, by Indication, 2023–2031

            13.4.1. Angle Closure Glaucoma (ACG)

            13.4.2. Open Angle Glaucoma (OAG)

            13.4.3. Secondary Glaucoma

            13.4.4. Congenital Glaucoma

            13.4.5. Other Indications

        13.5. Market Value Forecast, by Sales Channel, 2023–2031

            13.5.1. Hospital Pharmacies

            13.5.2. Retail Pharmacies

            13.5.3. Online Sales

        13.6. Market Value Forecast, by Country/Sub-region, 2023–2031

            13.6.1. Brazil

            13.6.2. Mexico

            13.6.3. Rest of Latin America

        13.7. Market Attractiveness Analysis

            13.7.1. By Product Type

            13.7.2. By Indication

            13.7.3. By Sales Channel

            13.7.4. By Country/Sub-region

    14. Middle East & Africa Glaucoma Treatment Market Analysis and Forecast

        14.1. Introduction

        14.2. Key Findings

        14.3. Market Value Forecast, by Product Type, 2023–2031

            14.3.1. Prostaglandin Analogs (PGAs)

            14.3.2. Alpha Agonist

            14.3.3. Beta Blockers

            14.3.4. Cholinergic

            14.3.5. Carbonic Anhydrase Inhibitors

            14.3.6. Combined Medications

        14.4. Market Value Forecast, by Indication, 2023–2031

            14.4.1. Angle Closure Glaucoma (ACG)

            14.4.2. Open Angle Glaucoma (OAG)

            14.4.3. Secondary Glaucoma

            14.4.4. Congenital Glaucoma

            14.4.5. Other Indications

        14.5. Market Value Forecast, by Sales Channel, 2023–2031

            14.5.1. Hospital Pharmacies

            14.5.2. Retail Pharmacies

            14.5.3. Online Sales

        14.6. Market Value Forecast, by Country/Sub-region, 2023–2031

            14.6.1. GCC Countries

            14.6.2. South Africa

            14.6.3. Rest of Middle East & Africa

        14.7. Market Attractiveness Analysis

            14.7.1. By Product Type

            14.7.2. By Indication

            14.7.3. By Sales Channel

            14.7.4. By Country/Sub-region

    15. Competition Landscape

        15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)

        15.2. Market Share Analysis, by Company (2022)

        15.3. Company Profiles

            15.3.1. Novartis AG

                15.3.1.1. Company Overview

                15.3.1.2. Product Portfolio

                15.3.1.3. SWOT Analysis

                15.3.1.4. Financial Overview

                15.3.1.5. Strategic Overview

            15.3.2. Pfizer, Inc.

                15.3.2.1. Company Overview

                15.3.2.2. Product Portfolio

                15.3.2.3. SWOT Analysis

                15.3.2.4. Financial Overview

                15.3.2.5. Strategic Overview

            15.3.3. Merck & Co., Inc.

                15.3.3.1. Company Overview

                15.3.3.2. Product Portfolio

                15.3.3.3. SWOT Analysis

                15.3.3.4. Financial Overview

                15.3.3.5. Strategic Overview

            15.3.4. Bausch & Lomb Inc.

                15.3.4.1. Company Overview

                15.3.4.2. Product Portfolio

                15.3.4.3. SWOT Analysis

                15.3.4.4. Financial Overview

                15.3.4.5. Strategic Overview

            15.3.5. Allergan Plc

                15.3.5.1. Company Overview

                15.3.5.2. Product Portfolio

                15.3.5.3. SWOT Analysis

                15.3.5.4. Financial Overview

                15.3.5.5. Strategic Overview

            15.3.6. Perrigo Plc

                15.3.6.1. Company Overview

                15.3.6.2. Product Portfolio

                15.3.6.3. SWOT Analysis

                15.3.6.4. Financial Overview

                15.3.6.5. Strategic Overview

            15.3.7. Teva Pharmaceutical Industries Ltd.

                15.3.7.1. Company Overview

                15.3.7.2. Product Portfolio

                15.3.7.3. SWOT Analysis

                15.3.7.4. Financial Overview

                15.3.7.5. Strategic Overview

            15.3.8. Akorn, Inc.

                15.3.8.1. Company Overview

                15.3.8.2. Product Portfolio

                15.3.8.3. SWOT Analysis

                15.3.8.4. Financial Overview

                15.3.8.5. Strategic Overview

            15.3.9. Mobius Therapeutics, LLC

                15.3.9.1. Company Overview

                15.3.9.2. Product Portfolio

                15.3.9.3. SWOT Analysis

                15.3.9.4. Financial Overview

                15.3.9.5. Strategic Overview

    List of Tables

    Table 01: Global Glaucoma Treatment Market Size (US$ Mn) Forecast, by Product Type, 2023–2031

    Table 02: Global Glaucoma Treatment Market Size (US$ Mn) Forecast, by Indication, 2023–2031

    Table 03: Global Glaucoma Treatment Market Size (US$ Mn) Forecast, by Sales Channel, 2023–2031

    Table 04: Global Glaucoma Treatment Market Size (US$ Mn) Forecast, by Region, 2023–2031

    Table 05: North America Glaucoma Treatment Market Size (US$ Mn) Forecast, by Country, 2023–2031

    Table 06: North America Glaucoma Treatment Market Size (US$ Mn) Forecast, by Product Type, 2023–2031

    Table 07: North America Glaucoma Treatment Market Size (US$ Mn) Forecast, by Indication, 2023–2031

    Table 08: North America Glaucoma Treatment Market Size (US$ Mn) Forecast, by Sales Channel, 2023–2031

    Table 09: Europe Glaucoma Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2023–2031

    Table 10: Europe Glaucoma Treatment Market Size (US$ Mn) Forecast, by Product Type, 2023–2031

    Table 11: Europe Glaucoma Treatment Market Size (US$ Mn) Forecast, by Indication, 2023–2031

    Table 12: Europe Glaucoma Treatment Market Size (US$ Mn) Forecast, by Sales Channel, 2023–2031

    Table 13: Asia Pacific Glaucoma Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2023–2031

    Table 14: Asia Pacific Glaucoma Treatment Market Size (US$ Mn) Forecast, by Product Type, 2023–2031

    Table 15: Asia Pacific Glaucoma Treatment Market Size (US$ Mn) Forecast, by Indication, 2023–2031

    Table 16: Asia Pacific Glaucoma Treatment Market Size (US$ Mn) Forecast, by Sales Channel, 2023–2031

    Table 17: Latin America Glaucoma Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2023–2031

    Table 18: Latin America Glaucoma Treatment Market Size (US$ Mn) Forecast, by Product Type, 2023–2031

    Table 19: Latin America Glaucoma Treatment Market Size (US$ Mn) Forecast, by Indication, 2023–2031

    Table 20: Latin America Glaucoma Treatment Market Size (US$ Mn) Forecast, by Sales Channel, 2023–2031

    Table 21: Middle East & Africa Glaucoma Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2023–2031

    Table 22: Middle East & Africa Glaucoma Treatment Market Size (US$ Mn) Forecast, by Product Type, 2023–2031

    Table 23: Middle East & Africa Glaucoma Treatment Market Size (US$ Mn) Forecast, by Indication, 2023–2031

    Table 24: Middle East & Africa Glaucoma Treatment Market Size (US$ Mn) Forecast, by Sales Channel, 2023–2031

    List of Figures

    Figure 01: Global Glaucoma Treatment Market Size (US$ Mn) and Distribution (%), by Region, 2023 and 2031

    Figure 02: Global Glaucoma Treatment Market Revenue (US$ Mn), by Product Type, 2022

    Figure 03: Global Glaucoma Treatment Market Value Share, by Product Type, 2022

    Figure 04: Global Glaucoma Treatment Market Revenue (US$ Mn), by Indication, 2022

    Figure 05: Global Glaucoma Treatment Market Value Share, by Indication, 2022

    Figure 06: Global Glaucoma Treatment Market Revenue (US$ Mn), by Sales Channel, 2022

    Figure 07: Global Glaucoma Treatment Market Value Share, by Sales Channel, 2022

    Figure 08: Global Glaucoma Treatment Market Value Share, by Region, 2022

    Figure 09: Global Glaucoma Treatment Market Value (US$ Mn) Forecast, 2023–2031

    Figure 10: Global Glaucoma Treatment Market Value Share Analysis, by Product Type, 2023 and 2031

    Figure 11: Global Glaucoma Treatment Market Attractiveness Analysis, by Product Type, 2023-2031

    Figure 12: Global Glaucoma Treatment Market Value Share Analysis, by Indication, 2023 and 2031

    Figure 13: Global Glaucoma Treatment Market Attractiveness Analysis, by Indication, 2023-2031

    Figure 14: Global Glaucoma Treatment Market Value Share Analysis, by Sales Channel, 2023 and 2031

    Figure 15: Global Glaucoma Treatment Market Attractiveness Analysis, by Sales Channel, 2023-2031

    Figure 16: Global Glaucoma Treatment Market Value Share Analysis, by Region, 2023 and 2031

    Figure 17: Global Glaucoma Treatment Market Attractiveness Analysis, by Region, 2023-2031

    Figure 18: North America Glaucoma Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2023–2031

    Figure 19: North America Glaucoma Treatment Market Attractiveness Analysis, by Country, 2023–2031

    Figure 20: North America Glaucoma Treatment Market Value Share Analysis, by Country, 2023 and 2031

    Figure 21: North America Glaucoma Treatment Market Value Share Analysis, by Product Type, 2023 and 2031

    Figure 22: North America Glaucoma Treatment Market Value Share Analysis, by Indication, 2023 and 2031

    Figure 23: North America Glaucoma Treatment Market Value Share Analysis, by Sales Channel, 2023 and 2031

    Figure 24: North America Glaucoma Treatment Market Attractiveness Analysis, by Product Type, 2023–2031

    Figure 25: North America Glaucoma Treatment Market Attractiveness Analysis, by Indication, 2023–2031

    Figure 26:North America Glaucoma Treatment Market Attractiveness Analysis, by Sales Channel, 2023–2031

    Figure 27: Europe Glaucoma Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2023–2031

    Figure 28: Europe Glaucoma Treatment Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 29: Europe Glaucoma Treatment Market Value Share Analysis, by Country/Sub-region, 2023 and 2031

    Figure 30: Europe Glaucoma Treatment Market Value Share Analysis, by Product Type, 2023 and 2031

    Figure 31: Europe Glaucoma Treatment Market Value Share Analysis, by Indication, 2023 and 2031

    Figure 32: Europe Glaucoma Treatment Market Value Share Analysis, by Sales Channel, 2023 and 2031

    Figure 33: Europe Glaucoma Treatment Market Attractiveness Analysis, by Product Type, 2023–2031

    Figure 34: Europe Glaucoma Treatment Market Attractiveness Analysis, by Indication, 2023–2031

    Figure 35: Europe Glaucoma Treatment Market Attractiveness Analysis, by Sales Channel, 2023–2031

    Figure 36: Asia Pacific Glaucoma Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2023–2031

    Figure 37: Asia Pacific Glaucoma Treatment Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 38: Asia Pacific Glaucoma Treatment Market Value Share Analysis, by Country/Sub-region, 2023 and 2031

    Figure 39: Asia Pacific Glaucoma Treatment Market Value Share Analysis, by Product Type, 2023 and 2031

    Figure 40: Asia Pacific Glaucoma Treatment Market Value Share Analysis, by Indication, 2023 and 2031

    Figure 41: Asia Pacific Glaucoma Treatment Market Value Share Analysis, by Sales Channel, 2023 and 2031

    Figure 42: Asia Pacific Glaucoma Treatment Market Attractiveness Analysis, by Product Type, 2023–2031

    Figure 43: Asia Pacific Glaucoma Treatment Market Attractiveness Analysis, by Indication, 2023–2031

    Figure 44: Asia Pacific Glaucoma Treatment Market Attractiveness Analysis, by Sales Channel, 2023–2031

    Figure 45: Latin America Glaucoma Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2023–2031

    Figure 46: Latin America Glaucoma Treatment Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 47: Latin America Glaucoma Treatment Market Value Share Analysis, by Country/Sub-region, 2023 and 2031

    Figure 48: Latin America Glaucoma Treatment Market Value Share Analysis, by Product Type, 2023 and 2031

    Figure 49: Latin America Glaucoma Treatment Market Value Share Analysis, by Indication, 2023 and 2031

    Figure 50: Latin America Glaucoma Treatment Market Value Share Analysis, by Sales Channel, 2023 and 2031

    Figure 51: Latin America Glaucoma Treatment Market Attractiveness Analysis, by Product Type, 2023–2031

    Figure 52: Latin America Glaucoma Treatment Market Attractiveness Analysis, by Indication, 2023–2031

    Figure 53: Latin America Glaucoma Treatment Market Attractiveness Analysis, by Sales Channel, 2023–2031

    Figure 54: Middle East & Africa Glaucoma Treatment Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2023–2031

    Figure 55: Middle East & Africa Glaucoma Treatment Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 56: Middle East & Africa Glaucoma Treatment Market Value Share Analysis, by Country/Sub-region, 2023 and 2031

    Figure 57: Middle East & Africa Glaucoma Treatment Market Value Share Analysis, by Product Type, 2023 and 2031

    Figure 58: Middle East & Africa Glaucoma Treatment Market Value Share Analysis, by Indication, 2023 and 2031

    Figure 59: Middle East & Africa Glaucoma Treatment Market Value Share Analysis, by Sales Channel, 2023 and 2031

    Figure 60: Middle East & Africa Glaucoma Treatment Market Attractiveness Analysis, by Product Type, 2023–2031

    Figure 61: Middle East & Africa Glaucoma Treatment Market Attractiveness Analysis, by Indication, 2023–2031

    Figure 62: Middle East & Africa Glaucoma Treatment Market Attractiveness Analysis, by Sales Channel, 2023–2031

Copyright © Transparency Market Research, Inc. All Rights reserved